Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director shareholdings and does not contain financial performance data.
Material Changes
On June 30, 2009, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of April 1, 2009, to June 30, 2009. The allocation price was set at £10.72 per Ordinary share and $35.54 per ADS. The specific allocations per director are as follows:
- Sir Christopher Gent: 43,462.43 Ordinary Shares
- Prof. Sir Roy Anderson: 4,375.53 Ordinary Shares
- Dr Stephanie Burns: 4,337.90 ADSs
- Mr Lawrence Culp: 15,537.94 ADSs
- Sir Crispin Davis: 33,257.85 Ordinary Shares
- Sir Deryck Maughan: 14,339.19 ADSs
- Mr James Murdoch: 201.82 Ordinary Shares
- Dr Daniel Podolsky: 6,847.75 ADSs
- Mr Tom de Swaan: 7,052.40 Ordinary Shares
- Sir Robert Wilson: 8,963.43 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares and ADSs allocated to Non-Executive Directors against the company's internal cap or plan limits.
- Confirm the allocation price of £10.72 per Ordinary share and $35.54 per ADS aligns with the market price on June 30, 2009.
- Ensure the service period (April 1, 2009, to June 30, 2009) matches the compensation committee's approved terms.
- Check subsequent filings to confirm if these provisional allocations were finalized or adjusted.